How Research Peptides Are Made

Every vial in our catalog starts as a string of letters — an amino-acid sequence — and becomes a physical molecule through solid-phase peptide synthesis (SPPS), the technique that won Bruce Merrifield the 1984 Nobel Prize in Chemistry. Knowing roughly how it works explains a lot about the product: why purity varies between manufacturers, why longer peptides cost more, and what the impurities on a COA actually are.

SPPS anchors the first amino acid to microscopic resin beads, then grows the chain in repeated cycles. Each cycle has two essential moves: deprotection, which removes the temporary chemical cap (in modern labs, the Fmoc group) from the last residue added, and coupling, which activates the next amino acid so it bonds to the freshly exposed end. Because the growing chain is tethered to solid beads, excess reagents are simply washed away between steps — that is the trick that makes the repetition practical.

The catch is that no coupling is 100% efficient. If each step succeeds 99% of the time, a 30-residue peptide finishes with only about 74% of chains fully correct; the rest carry a missing or truncated residue. This is why sequence length drives both cost and difficulty, and why the raw ('crude') product of any synthesis is far from pure.

After the final residue, a cleavage cocktail releases the peptide from the resin and strips the side-chain protecting groups. What comes off is a mixture: the target plus its deletion and truncation cousins. Purification is preparative reversed-phase HPLC — the industrial-scale sibling of the analytical technique described in the HPLC explainer — which physically separates the target peak and discards the rest.

The purified solution is then freeze-dried into the stable white cake you receive (see storage basics), and a sample of the finished lot goes out for the identity, purity, and endotoxin testing recorded on its certificate. The chain of evidence ends in the COA library; the chain of chemistry ends in your freezer.